favicon-300x300

ERS Genomics

ERS is the world leader in licensing CRISPR/Cas9 technology for a wide variety of applications.
 
Our founder, Dr. Emmanuelle Charpentier (the ‘E’in ERS) won the Nobel Prize the discovery of CRISPR/Cas9 in 2020. 

Without question, CRISPR/Cas9 has transformed the field of gene editing. At ERS Genomics, our purpose is to extend global access to this technology and expand the boundaries of CRISPR potential.
 
 
 
 

 

BIO-Europe is the perfect time to start a conversation about your CRISPR license. We are excited to connect with companies who can benefit from this game-changing technology.
A meeting or a call with us is worthwhile for you if:

You are interested in possible use of CRISPR/Cas9 for internal research programs:
– Are you using modified cells or animals from an academic source?
– Are you generating in-house reagents?

 

You are interested in use of genetically modified cells in manufacturing. Including… 
– mAbs
– Gene or cell therapy
– Vectors
– Industrial enyzmes or intermediates

 

You provide any services which utilize CRISPR/Cas9 or cells or animals modified by the technology. Including…
– High-throughput screening 
– Target identification, Target validation
– Cell line development
– Disease specific cell models
– Animal models of disease

 

You have an interest in animal health applications. Including… 
– Disease resistance, Vaccines Trait improvements

 
 
Let’s schedule a meeting in Basel

Schedule time with Dr. Ralph Vogelsang, Senior Director, Business Development & Licensing, ERS Genomics

‘Your journey with CRISPR begins with a license from ERS Genomics. I am delighted to be back at BIO 2023. If you would like to learn more about CRISPR/Cas9 and licensing, connect with me and let’s talk.’

Schedule a Meeting
Bio Partnering

Licensing

Learn More

Intellectual Property

Learn More

Knowledge Centre

Learn More

Contact US

Learn More

Read More Of Our Articles

Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.

AI + CRISPR: Powering the 21st Century’s Biological Revolution 

We stand at the forefront of a pivotal moment in human innovation—where AI and CRISPR gene editing converge to power what can only be described as the 21st century’s biological revolution.  A New Industrial Epoch  Just as coal and steam powered the 19th-century Industrial Revolution and electricity and chemistry fuelled.

Read Full Article

Licensee Case Study: Bioneer

Making CRISPR more accessible for scientific innovation   At ERS Genomics, we make CRISPR/Cas9 accessible to innovators. By licensing the foundational IP co-owned by Professor Emmanuelle Charpentier, we enable a broad spectrum of applications outside of direct therapeutic use—from drug discovery to innovation in fields far beyond pharma. One of.

Read Full Article

ERS Genomics and Jumpcode Genomics sign CRISPR/Cas9 license agreement 

License agreement provides Jumpcode Genomics access to CRISPR gene editing technology to enhance next-generation sequencing capabilities    Dublin, Ireland, and San Diego, CA, 27 March, 2025: ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Jumpcode Genomics (‘Jumpcode’), a life science tools company improving and reducing the cost of next-generation.

Read Full Article